Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2016 - 2019)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Account Payables for 4 consecutive years, with $3.9 million as the latest value for Q3 2019.

  • On a quarterly basis, Change in Account Payables rose 298.58% to $3.9 million in Q3 2019 year-over-year; TTM through Sep 2019 was $4.2 million, a 517.67% increase, with the full-year FY2018 number at $3.4 million, down 2.52% from a year prior.
  • Change in Account Payables was $3.9 million for Q3 2019 at Ultragenyx Pharmaceutical, up from -$3.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q4 2018 to a low of -$3.5 million in Q2 2019.
  • A 4-year average of $639933.3 and a median of $187000.0 in 2016 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 1698.93% in 2017; the steepest drop was 343.26% in 2017.
  • Ultragenyx Pharmaceutical's Change in Account Payables stood at -$1.3 million in 2016, then skyrocketed by 68.66% to -$420000.0 in 2017, then skyrocketed by 1044.05% to $4.0 million in 2018, then decreased by 1.39% to $3.9 million in 2019.
  • Per Business Quant, the three most recent readings for RARE's Change in Account Payables are $3.9 million (Q3 2019), -$3.5 million (Q2 2019), and -$151000.0 (Q1 2019).